Core Viewpoint - Beijing Sinocell Biotechnology Group Co., Ltd. has received approval from the China Securities Regulatory Commission for its application to issue shares to specific investors for the year 2025 [1][3]. Group 1 - The company has been granted registration approval for the issuance of shares to specific investors, as per the approval document issued by the China Securities Regulatory Commission [1]. - The issuance must strictly follow the declaration documents and issuance plan submitted to the Shanghai Stock Exchange [2]. - The approval is valid for 12 months from the date of registration consent, and the company must report any significant events to the Shanghai Stock Exchange before the issuance is completed [3]. Group 2 - The company’s board will handle the issuance matters within the stipulated timeframe and fulfill information disclosure obligations as required by the approval document and relevant laws [3]. - Contact information for the company and its sponsor (lead underwriter) is provided for investor inquiries [4]. - The announcement was made by the board of directors of Beijing Sinocell Biotechnology Group Co., Ltd. on January 6, 2026 [5].

Group 1: Regulatory Developments - The National Healthcare Security Administration (NHSA) is seeking public opinions on the draft guidelines for the real-world comprehensive value assessment of medical services, aiming to establish a unified evaluation system across the country [1] - CanSino Biologics has received approval for clinical trials of its 24-valent pneumococcal polysaccharide conjugate vaccine, which targets major circulating serotypes and is intended for individuals aged 2 months and older [2] - Merck has announced that its breakthrough therapy, Sotatercept, has been approved in China for treating adult patients with pulmonary arterial hypertension (PAH), based on data from the STELLAR Phase III clinical trial [3] - ST. Renfu has received approval for clinical trials of HW221043 tablets, intended for the treatment of advanced solid tumors, with no similar drugs currently approved in the market [4] - Heng Rui Medicine has received approval for clinical trials of HRS-4357 injection and HRS-5041 tablets, aimed at treating PSMA-positive prostate cancer [5] Group 2: Market Activities - Shenzhou Cell has received approval from the China Securities Regulatory Commission for its application to issue stocks to specific investors [6] - Tianchen Medical has signed a strategic cooperation agreement with Inspur Digital Technology to promote innovation in medical intelligent manufacturing and robotics [7] - Zhonghong Medical's subsidiary has participated in a bidding project for centralized procurement of medical consumables, with some products expected to be selected, enhancing market presence [8] - Yifan Pharmaceutical's subsidiary has signed an exclusive agreement with Shangde Yaoyuan for the ACT001 drug, involving a total payment of 1 billion yuan [9] - Yijiahe is exploring the application of "brain-computer interface + embodied intelligent robots" technology in smart healthcare scenarios, having signed a strategic cooperation agreement with Mairande [10]

Core Viewpoint - Shenzhou Cell (688520) has received approval from the China Securities Regulatory Commission (CSRC) for a specific stock issuance, which is expected to enhance its capital structure and support future growth initiatives [1][2] Group 1: Stock Performance - As of January 5, 2026, Shenzhou Cell's stock closed at 46.9 yuan, marking an increase of 8.29% from the previous trading day [1] - The stock opened at 43.25 yuan, reached a high of 47.25 yuan, and a low of 43.18 yuan during the trading session [1] - The total market capitalization of the company is reported at 20.886 billion yuan, with a trading volume of 2.88 billion yuan and a turnover rate of 1.41% [1] Group 2: Regulatory Approval - The company has received a formal approval from the CSRC for its application to issue stocks to specific investors, as indicated in the official document (Approval No. 2971) [1] - The approval is valid for 12 months from the date of issuance, allowing the company to proceed with the necessary issuance procedures within the stipulated timeframe [1]

Core Viewpoint - The company, Beijing Shenzhou Cell Biotechnology Group Co., Ltd., has received approval from the China Securities Regulatory Commission for its application to issue stocks to specific investors [1] Group 1 - The approval is documented in the official notice numbered 2971, indicating the regulatory endorsement for the company's stock issuance [1]

Core Viewpoint - Shenzhou Cell has received approval from the China Securities Regulatory Commission for its stock issuance to specific investors, indicating a significant step in its capital-raising efforts [1] Group 1 - The company has been granted a registration approval for issuing stocks to specific objects, as per the regulatory document numbered 2971 [1]

Core Viewpoint - Shenzhou Cell has received approval from the China Securities Regulatory Commission (CSRC) for its stock issuance to specific investors, aiming to raise up to 900 million yuan for liquidity support [1] Group 1 - The company announced the approval on January 5, indicating a significant step in its capital-raising efforts [1] - The total amount to be raised from the stock issuance is capped at 900 million yuan, which includes the principal amount [1] - After deducting issuance costs, the entire raised amount is intended to be used for supplementing the company's working capital [1]

Core Viewpoint - Shenzhou Cell has received approval from the China Securities Regulatory Commission for its application to issue stocks to specific investors [1] Group 1 - The company announced on January 5 that it has received a formal approval from the regulatory authority [1] - The approval pertains to the company's registration application for issuing stocks to specific targets [1]

证券代码：688520 证券简称：神州细胞 公告编号：2026-001 北京神州细胞生物技术集团股份公司 关于 2025 年度向特定对象发行股票申请获得 中国证券监督管理委员会同意注册批复的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京神州细胞生物技术集团股份公司（以下简称"公司"）于近日收到中国 证券监督管理委员会出具的《关于同意北京神州细胞生物技术集团股份公司向特 定对象发行股票注册的批复》（证监许可〔2025〕2971号）（以下简称"批复文 件"），具体内容如下： "一、同意你公司向特定对象发行股票的注册申请。 二、你公司本次发行应严格按照报送上海证券交易所的申报文件和发行方案 实施。 三、本批复自同意注册之日起 12 个月内有效。 公司董事会将按照上述批复文件和相关法律法规的要求以及公司股东会的 授权，在规定期限内办理本次向特定对象发行股票的相关事项，并及时履行信息 披露义务，敬请广大投资者注意投资风险。 公司（发行人）、保荐人（主承销商）的联系方式如下： 1、发行人：北京神州细胞生物技术集团股份公司 ...

证券日报网讯 12月29日，神州细胞发布公告称，公司2025年12月29日召开第二次临时股东会，审议通 过《关于聘请公司2025年度审计机构的议案》《关于2026年度对外捐赠额度的议案》《关于修订公司部 分制度的议案》等多项议案。 （编辑 丛可心） ...

北京市金杜律师事务所 关于北京神州细胞生物技术集团股份公司 2025 年第二次临时股东会的法律意见书 致：北京神州细胞生物技术集团股份公司 北京市金杜律师事务所（以下简称本所）接受北京神州细胞生物技术集团股 份公司（以下简称公司）的委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督 管理委员会（以下简称中国证监会）《上市公司股东会规则（2025 修订）》（以 下简称《股东会规则》）等中华人民共和国境内（以下简称中国境内，为本法律 意见书之目的，不包括中国香港特别行政区、中国澳门特别行政区和中国台湾省） 现行有效的法律、行政法规、部门规章、规范性文件和现行有效的《北京神州细 胞生物技术集团股份公司章程》（以下简称《公司章程》）的规定，指派律师出 席了公司于 2025 年 12 月 29 日召开的 2025 年第二次临时股东会（以下简称本次 股东会），并就本次股东会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2024 年年度股东大会审议通过的现行有效的《公司章程》； 2. 公司 ...